Home
Alphamab Oncology

Alphamab Oncology Market Share Analysis for May 2026

康宁杰瑞生物制药专注于研发、生产和商业化创新抗肿瘤药物。2019年12月12日，公司在香港联合交易所主板上市，股票代码：9966。

Health > Biotechnology and Pharmaceuticals

Domainalphamabonc.com

Year Founded2015

Employees201 - 500

Annual Revenue$50M - $75M

Alphamab Oncology

Alphamab Oncology (including company regionals)

alphamabonc.com

See more website traffic and engagement information

Alphamab Oncology Revenue up to May 2026 is 50M - 75M

revenue generated by Alphamab Oncology top domains

Alphamab Oncology top domains revenue over 3 years

Revenue for Alphamab Oncology top domains

alphamabonc.com50M - 75M

See more with Sales Intelligence

Total visits to Alphamab Oncology's top domains

Understand Alphamab Oncology market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

alphamabonc.com4K

See more with Sales Intelligence

Avg. visit duration in Alphamab Oncology's top domains

Analyze Alphamab Oncology engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

alphamabonc.com00:00:18

See more with Sales Intelligence

Avg. pageviews on Alphamab Oncology's top domains

See how Alphamab Oncology keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

alphamabonc.com1.82

See more with Sales Intelligence

Alphamab Oncology top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Alphamab Oncology

These are the website technologies, by industry, used by Alphamab Oncology top domains

Advertising (1)

PubMatic

eCommerce (1)

Swap

Mobile (1)

Meta Viewport

Social (1)

Baidu Share

More Technologies

1

See all

News & Signals from Alphamab Oncology

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAlphamabonc attends event ASCO 2026.Alphamab Oncology to present Phase 1 data on bispecific ADC JSKN016 in her2-negative breast cancer at ASCO 2026.

NewsAlphamabonc launched Investigational New Drug application for JSKN021 on Mar 13th '26.SUZHOU, China, March 13, 2026 /PRNewswire/ - Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate (ADC) targeting EGFR and HER3, has been officially accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).